We have performed an in-vivo study with the new formulation in an established hair growth model in mice. After application of the highest dose five times a week we observed a clear increase in hair growth. The positive results from the in vivo study are very important since we received concrete evidence that the treatment with the formulation really works, with a demonstrated stimulation of hair growth. In the study we also compared FOL-005 with an established treatment, Minoxidil 5% administrated twice daily, and the results for both treatments were during the main part of the study equal.

Follicum filed a patent application for the new topical formulation during the spring. The formulation is intended for application on the scalp and has demonstrated good hair stimulating effect in an animal model. If the patent application is approved, the protection for FOL-005 will be extended with 8 years. The next step for the formulation is to be tested in the clinical phase II trial on alopecia patients, which is planned to start at the end of 2019.

In the beginning of 2019, Follicum employed two post-doctoral scientists to establish an in-house laboratory for in vitro studies of Follicum’s peptides and the effects on diabetes and its complications.

LUDC (Lund University Diabetes Centre) has been granted a post-doc to study the Mode of Action (MoA) of our diabetes peptides. Dr Chrysostomi Gialeli is the latest addition of resources to Follicum on a post-doc employment to speed up the research with the aim to strengthening the potential of Follicum’s peptides for future diabetes treatment.

Follicum received an official grant of patent from the European Patent Office, EPO regarding the company’s broadened patent application for stimulation of hair growth. With EPO’s grant of the patent there is now broad protection for Follicum’s peptides in Europe until 2032.

Follicum established a Scientific Advisory Board in the diabetes field. The purpose is to strengthen knowledge transfer from academic research to clinical application and commercialization. The Board consists of 5 internationally reputable experts with extensive experience in research into diabetes and its complications.

The Korean patent office (”KIPO”) approved the company’s patent application for stimulation of hair growth. With this approval, Follicum has a patent protection in Korea up to and including year 2032. The patent protects the company’s peptides in general and for stimulation of hair growth in particular.

Follicum received Notice of Allowance from the U.S. Patent Office for method of stimulating hair growth with FOL-005.

Follicum signed a cooperation agreement with Bioglan AB for the production of clinical trial material of Follicum’s new, cream-like formulation of FOL-005 for topical treatment. The formulation will be used in the Phase II clinical trial on hair loss, which is expected to start in the beginning of 2020.

Follicum successfully completed the supplementary toxicology studies that will form the basis of the forthcoming clinical study with the topical formulation of FOL-005.

Follicum’s application for a Eurostars grant comprising the development of a first-in-class treatment for diabetes was approved. Follicum is the coordinator of the project. Other partners include Lund University, Bioassay Labor für biologische Analytik GmbH and Deutsche Diabetes-Forschungsgesellschaft (DDZ).

Follicum signed a collaboration agreement with proDERM for conducting the new clinical trial with a cream-like formulation of FOL-005 to be tested on alopecia patients (patients with hair loss).


Follicum has developed a user-friendly topical formulation with good stability and penetration. We chose the formulation in June, and this formulation will now be scaled-up and will later be tested in clinical phase II and phase III trials before registration and launch of the product.

The results from the clinical phase II trial with injection showed that the hair growth increased during the trial period with 7 hairs per cm2 in average at the highest dose of FOL-005. A clear positive effect was also shown in the number of hairs in growth phase, especially at the highest tested dose, while the placebo group showed a clear decrease instead.

In the diabetes project, our patented peptides have shown interesting effects in preclinical studies on the release of insulin, amongst other things. The project is rapidly advancing, and we filed a new patent application in November to broaden our protection. This latest patent application will protect new aspects discovered in the preclinical studies of the peptide class. Experimental studies also show that our new optimized peptides have a protective and conservative effect on beta cells that have been exposed to high concentrations of glucose during a long period. The results, that are clearly positive, show that our peptide classes have the potential to become a valuable complement in the treatment of diabetes. Follicum selected a drug candidate early 2019 and we are now preparing the project for future clinical trials.


Our clinical phase I/IIa trial with FOL-005 was completed at the beginning of 2017, and showed a good safety of the treatment. The results also showed a clear stimulation of hair growth that was statistically significant. See FOL-005. The trials were carried out at the Clinical Research Centre (CRC) of the Charité University Hospital in Berlin.

In parallel with our development of FOL-005 we continue the pre-clinical trials with other peptides, among these FOL-014, which early on showed an increased release of insulin from the pancreas in in-vitro studies.

The Diabetes Research Group led by Professor Jan Nilsson at the Clinical Research Centre of Lund University receives a substantial financing from the Novo Nordisk Foundation to widen the pre-clinical research on diabetes with the Follicum peptides.

During spring 2017 Follicum was invited to become a partner in a very comprehensive research project with the University of Lund in diabetes research. This project has received a considerable funding of up to 100 MSEK from the Swedish Foundation for Strategic Research. Read more: (Only in Swedish) Research cooperations.

Follicum is also actively pursuing different projects for the formulation of the treatment with FOL-005, ointments, cream, powder and other preparation, preparing for up-coming clinical trials.


Follicum initiated a clinical phase I/IIa trial at the University Hospital Charité In Berlin in order to study safety and effect of the drug candidate FOL-005.


Follicum carried out several toxicity trials as a preparation for upcoming clinical trials on humans.


Follicum was awarded 50 000 SEK from the Swedish fund ALMI in order to carry out a pre-study in dermatology applications.

Follicum began a collaboration with Professor Amos Gilhar at the Haifa University (Technion).

Follicum was listed on the Swedish small-cap exchange Spotlight Stock Market (formerly AktieTorget) on November 25, 2014.


Follicum received a further 3.5 MSEK from Vinnova’s grant “Forska & Väx” (Research & Growth) after showing positive results in pre-clinical studies. Lund University Bioscience invested another 2 MSEK.

Dr Jan Alenfall was appointed CEO.


The company received 500 KSEK (roughly 60 KUSD) from Vinnova to perform additional studies to strengthen the projects’ potential.

Collaboration with Professor Ralf Paus, University of Lübeck, was initiated and interesting pre-clinical results on Follicum’s studies was obtained from Dabur Research Foundation in India.

Lund University Bioscience AB invested 3.7 MSEK and Sunstone Capital, Denmark, invests 4 MSEK (roughly 470 KUSD).


Follicum AB is founded.

A pre-clinical experiment is finished, showing that Follicum’s peptides modulate hair growth in mice. New peptides are synthesized and a patent application for hair growth is filed.


The founders of the company discover, in connection with research on arteriosclerosis, that a modified protein increases hair growth in mice.